Department of Surgery, Sahlgrenska University Hospital, Sahlgrenska Academy, University of Gothenburg, SE-413 45, Gothenburg, Sweden.
Endocrine. 2013 Aug;44(1):228-36. doi: 10.1007/s12020-012-9856-z. Epub 2012 Dec 20.
The aim of this study was to assess patient-reported impacts and health-related quality of life (HRQL) of a 2-year follow-up programme in a large cohort of patients with stationary, non-functioning, adrenal incidentalomas (AIs) in western Sweden. 145 patients (mean age 68 years, 62 % females) with AI from a prospective study in western Sweden were studied. All had completed a 2-year follow-up programme by November 2007, without evidence of adrenal malignancy or hormone over-production. To evaluate patient-reported impacts and HRQL, an eight-item adrenal incidentaloma impact questionnaire was used retrospectively, together with the hospital anxiety and depression scale, and the short form-36. There were 111 patients (mean age 67 years, 63 % females) who responded to the questionnaire (response rate 77 %). 77 % reported that the AI diagnosis had caused them to be worried; however, fewer than 20 % had thought about the lesion often during the follow-up programme, and only 3 % had felt that it had a large impact on their current daily life. Only 4 % stated that the follow-up programme had been a negative experience, nevertheless 10 % reported a negative impact on their HRQL during the follow-up programme. Only 2 % stated that release from follow-up caused worry to any degree. In total, 29 % had possible anxiety, and 30 % had possible depression, probably reflecting significant co-morbidity. Possible anxiety correlated with a more negative experience of the follow-up programme. In conclusion, the 2-year follow-up programme for patients with AI was well tolerated. Nonetheless, a small number remained worried throughout follow-up, suggesting the need for tailored counselling in individual patients to ameliorate negative impacts of follow-up.
本研究旨在评估在瑞典西部一个大型固定性、无功能性肾上腺偶发瘤(AIs)患者队列中进行的为期 2 年的随访方案对患者报告的影响和健康相关生活质量(HRQL)的影响。145 名来自瑞典西部前瞻性研究的 AI 患者(平均年龄 68 岁,62%为女性)参与了研究。所有患者均在 2007 年 11 月前完成了为期 2 年的随访方案,无肾上腺恶性肿瘤或激素过度分泌的证据。为了评估患者报告的影响和 HRQL,使用了 8 项肾上腺偶发瘤影响问卷进行回顾性评估,同时还使用了医院焦虑和抑郁量表以及简短形式 36 项健康调查量表。有 111 名患者(平均年龄 67 岁,63%为女性)对问卷做出了回应(应答率为 77%)。77%的患者报告称 AI 诊断使他们感到担忧;然而,在随访期间,不到 20%的患者经常想到病变,只有 3%的患者认为它对他们目前的日常生活有很大影响。只有 4%的患者表示随访方案是一种负面体验,尽管如此,仍有 10%的患者报告在随访期间对他们的 HRQL 产生了负面影响。只有 2%的患者表示从随访中解脱出来会引起任何程度的担忧。总的来说,29%的患者可能有焦虑,30%的患者可能有抑郁,这可能反映出显著的合并症。可能的焦虑与对随访方案更负面的体验相关。总之,AI 患者的 2 年随访方案耐受性良好。尽管如此,仍有一小部分患者在整个随访期间感到担忧,这表明需要为个别患者提供定制化的咨询,以减轻随访带来的负面影响。